STOCK TITAN
  1. Home
  2. Sec-filings
  3. CLPT
  4. [Form 4] ClearPoint Neuro, Inc. Insider Trading Activity

Director Pascal Girin converts 12,417 RSUs into ClearPoint Neuro (CLPT) common shares

Filing Impact
(Neutral)
Filing Sentiment
(Neutral)
Form Type
4

Rhea-AI Filing Summary

ClearPoint Neuro director Pascal E. R. Girin settled a restricted stock unit award into common shares. On May 19, 2026, he exercised 12,417 restricted stock units, receiving 12,417 shares of ClearPoint Neuro, Inc. common stock at no cash exercise price. After this settlement, he directly holds 110,623 common shares. The RSUs were originally granted on May 22, 2025 and vested on their scheduled vesting date tied to the earlier of the first anniversary of grant or the day before the company’s 2026 annual meeting of stockholders.

Positive

  • None.

Negative

  • None.
Insider Girin Pascal E R
Role null
Type Security Shares Price Value
Exercise Restricted Stock Units 12,417 $0.00 --
Exercise Common Stock 12,417 $0.00 --
Holdings After Transaction: Restricted Stock Units — 0 shares (Direct, null); Common Stock — 110,623 shares (Direct, null)
Footnotes (1)
  1. [object Object]
RSUs exercised 12,417 units Restricted stock units settled into common stock on May 19, 2026
Common shares acquired 12,417 shares Shares received from RSU settlement on May 19, 2026
Shares held after transaction 110,623 shares Director’s direct common stock holdings following the RSU settlement
RSU grant date May 22, 2025 Grant date for the 12,417 restricted stock units
Restricted Stock Units financial
"Each restricted stock unit represents a contingent right to receive one share of ClearPoint Neuro, Inc. common stock."
Restricted stock units are a type of company reward where employees are promised shares of stock, but they only fully own these shares after meeting certain conditions, like staying with the company for a set time. They matter because they can become valuable assets and are often used to motivate employees to help the company succeed.
derivative security financial
"transaction_code_description": "Exercise or conversion of derivative security""
A derivative security is a financial contract whose value comes from the price or performance of something else, such as a stock, bond, commodity, or market index. For investors it acts like an insurance policy or a wager: it can be used to protect against losses, lock in prices, or amplify gains and losses, so it can change a portfolio’s risk and potential return without owning the underlying asset directly.
scheduled vesting date financial
"This transaction represents the settlement of restricted stock units in shares of common stock on their scheduled vesting date."
annual meeting of stockholders financial
"the day immediately preceding the Company's 2026 annual meeting of stockholders"
Form 4 Insider Transactions: What Each Field Means →
SEC Form 4
FORM 4UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number:3235-0287
Estimated average burden
hours per response:0.5
X
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
Girin Pascal E R
(Last)(First)(Middle)
C/O CLEARPOINT NEURO, INC.
120 S. SIERRA AVE., SUITE 100
(Street)
SOLANA BEACH CALIFORNIA 92075
(City)(State)(Zip)
UNITED STATES
(Country)		2. Issuer Name and Ticker or Trading Symbol
ClearPoint Neuro, Inc. [ CLPT ] 		5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
XDirector10% Owner
Officer (give title below)Other (specify below)
2a. Foreign Trading Symbol
3. Date of Earliest Transaction (Month/Day/Year)
05/19/2026		6. Individual or Joint/Group Filing (Check Applicable Line)
XForm filed by One Reporting Person
Form filed by More than One Reporting Person
4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year)2A. Deemed Execution Date, if any (Month/Day/Year)3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeVAmount(A) or (D)Price
Common Stock05/19/2026M12,417A(1)110,623D
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year)3A. Deemed Execution Date, if any (Month/Day/Year)4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year)7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeV(A)(D)Date ExercisableExpiration DateTitleAmount or Number of Shares
Restricted Stock Units(1)05/19/2026M12,417 (1) (1)Common Stock12,417(1)0D
Explanation of Responses:
1. Each restricted stock unit represents a contingent right to receive one share of ClearPoint Neuro, Inc. ("CLPT") common stock. On May 22, 2025, the reporting person was granted 12,417 restricted stock units, vesting on the earlier of (i) the first anniversary of the grant date, or (ii) the day immediately preceding the Company's 2026 annual meeting of stockholders. This transaction represents the settlement of restricted stock units in shares of common stock on their scheduled vesting date.
/s/ Danilo D'Alessandro, by Power of Attorney for Pascal E. R. Girin05/21/2026
** Signature of Reporting PersonDate
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

Source: View Original Filing on SEC EDGAR

FAQ

What insider transaction did ClearPoint Neuro (CLPT) director Pascal Girin report?

Pascal Girin reported settling restricted stock units into shares. On May 19, 2026, he exercised 12,417 restricted stock units, receiving 12,417 shares of ClearPoint Neuro common stock as part of a scheduled vesting event, rather than an open-market purchase or sale.

How many ClearPoint Neuro (CLPT) shares did Pascal Girin acquire in this Form 4?

Pascal Girin acquired 12,417 common shares through RSU settlement. These shares came from the exercise of 12,417 restricted stock units that vested according to their grant terms, with no cash exercise price reported for the conversion.

What are the vesting terms of Pascal Girin’s ClearPoint Neuro (CLPT) RSUs?

The RSUs were time-based and tied to the annual meeting schedule. Granted on May 22, 2025, the 12,417 restricted stock units vested on the earlier of the first anniversary of that grant date or the day immediately before ClearPoint Neuro’s 2026 annual stockholders’ meeting.

How many ClearPoint Neuro (CLPT) shares does Pascal Girin hold after this transaction?

After the RSU settlement, Pascal Girin holds 110,623 shares. The Form 4 shows his direct ownership of ClearPoint Neuro common stock increased by 12,417 shares, reflecting the full conversion of his vested restricted stock units into common stock.

Was Pascal Girin’s ClearPoint Neuro (CLPT) Form 4 a market sale or purchase?

The Form 4 reflects an RSU exercise, not a market trade. The transaction code "M" and zero exercise price indicate a derivative exercise and settlement of restricted stock units into common stock, rather than buying or selling shares on the open market.